RPL554: Ph IIa started

Verona began a double-blind, placebo-controlled, 3-way crossover, U.K. Phase IIa trial to evaluate single doses of 1.5 and 6 mg inhaled RPL554 in about 10 patients. In 2005, Verona licensed the produc...